Pentose Phosphate Pathway

Overview

The pentose phosphate pathway (PPP), also known as the hexose monophosphate shunt, is an alternative route for glucose-6-phosphate metabolism that operates in the cytoplasm of all cells. Unlike glycolysis, which is designed for ATP production, the PPP serves two primary purposes: generation of NADPH (the cell's primary reductive currency for biosynthesis and antioxidant defense) and production of ribose-5-phosphate (a precursor for nucleotide and nucleic acid synthesis).

The PPP is particularly active in tissues with high biosynthetic demands (liver, adipose tissue, adrenal cortex, mammary gland) and in cells requiring robust antioxidant capacity (red blood cells, lens of the eye, neutrophils). The pathway does not generate or consume ATP directly.

How It Works

Oxidative Phase (Irreversible)

The oxidative phase generates NADPH and ribulose-5-phosphate:

1. Glucose-6-phosphate dehydrogenase (G6PD) — Oxidizes glucose-6-phosphate to 6-phosphoglucono-delta-lactone, producing the first NADPH. This is the rate-limiting and committed step.
2. Lactonase — Hydrolyzes the lactone to 6-phosphogluconate.
3. 6-Phosphogluconate dehydrogenase — Oxidatively decarboxylates 6-phosphogluconate to ribulose-5-phosphate, producing the second NADPH and releasing CO2.

Net: 1 glucose-6-phosphate yields 2 NADPH + 1 ribulose-5-phosphate + 1 CO2.

Non-Oxidative Phase (Reversible)

The non-oxidative phase interconverts sugars between three-, four-, five-, six-, and seven-carbon forms through transketolase and transaldolase reactions. This allows the cell to:

• Convert ribulose-5-phosphate to ribose-5-phosphate when nucleotide synthesis is needed
• Recycle carbon skeletons back to glycolytic intermediates (fructose-6-phosphate and glyceraldehyde-3-phosphate) when NADPH is the primary need
• Flexibly adjust the ratio of NADPH to ribose-5-phosphate production based on cellular demands

Regulation

G6PD is regulated primarily by the NADP+/NADPH ratio. When NADPH is consumed (by biosynthesis or antioxidant recycling), the rising NADP+ concentration activates G6PD, increasing pathway flux. Insulin upregulates G6PD expression, linking the PPP to the fed-state metabolic program.

Key Components

• Glucose-6-phosphate dehydrogenase (G6PD) — Rate-limiting enzyme, regulated by NADP+ availability
• NADPH — The reductive cofactor produced by the oxidative phase
• Ribose-5-phosphate — The pentose sugar used for DNA/RNA synthesis
• Transketolase — Non-oxidative phase enzyme requiring thiamine pyrophosphate (vitamin B1)
• Glutathione reductase — Uses PPP-derived NADPH to regenerate reduced glutathione

Peptide Connections

The PPP connects to peptide biology primarily through its roles in antioxidant defense and biosynthetic support:

Glutathione is the body's master intracellular antioxidant, and its regeneration depends entirely on PPP-derived NADPH. Glutathione reductase uses NADPH to convert oxidized glutathione (GSSG) back to its active reduced form (GSH). This makes the PPP the lifeline of the glutathione antioxidant system. Supplementation strategies aimed at boosting glutathione levels are only effective if NADPH supply from the PPP is adequate to maintain the GSH/GSSG redox couple.

SS-31 (elamipretide) reduces mitochondrial reactive oxygen species production, thereby decreasing the oxidative burden on cytoplasmic antioxidant systems including the glutathione-NADPH cycle. By mitigating ROS at their source, SS-31 indirectly reduces the demand on the PPP for NADPH regeneration of glutathione.

NAD+ precursors are relevant because NADPH and NADH, while carrying similar names, serve distinct metabolic roles. The PPP generates NADPH specifically for reductive biosynthesis, while NAD+ (maintained by NAD+ precursor supplementation) serves oxidative catabolic pathways. Proper balance between both pools is essential for metabolic health.

Insulin upregulates G6PD and several other PPP enzymes at the transcriptional level, increasing NADPH production in the fed state. This NADPH feeds into lipogenesis (fatty acid synthase requires NADPH) and supports the anabolic program activated by insulin signaling. Insulin resistance can impair this coordination, reducing NADPH supply for both biosynthetic and antioxidant functions.

Clinical Significance

G6PD deficiency is the most common human enzyme deficiency, affecting over 400 million people worldwide. Because red blood cells lack mitochondria and depend entirely on the PPP for NADPH (and thus glutathione recycling), G6PD-deficient individuals are susceptible to hemolytic anemia triggered by oxidant stressors including certain drugs (primaquine, sulfonamides), infections, and fava beans.

In cancer biology, many tumors upregulate the PPP to support rapid nucleotide synthesis for proliferation and to maintain redox balance under the increased oxidative stress of malignant growth. PPP inhibition is being explored as a therapeutic strategy to sensitize tumors to oxidative damage.

Related Topics

• Glycolysis — Shares glucose-6-phosphate as the branch point substrate
• Lipogenesis — Major consumer of PPP-derived NADPH for fatty acid synthesis
• Krebs Cycle — Carbon skeletons from the PPP can re-enter central metabolism
• Inflammation Response — Neutrophils use PPP-derived NADPH for the oxidative burst
• DNA Replication — Requires ribose-5-phosphate from the PPP for nucleotide synthesis